Illumina (ILMN) Tops Q4 EPS by 3c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil rises as Trump repeats Iran attack threat
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Barclays Downgrades Illumina (ILMN) to Underweight
February 10, 2025 6:13 AM ESTBarclays analyst Luke Sergott downgraded Illumina (NASDAQ: ILMN) from Equalweight to Underweight with a price target of $100.00 (from $130.00).
The analyst comments "Overall, we view ILMN as a great business with a technological edge that has matured along with the market it created. We think that it is a normal Tools business not unlike other mature genomics / proteomics markets like PCR and mass spec. These are solid MSD topline growers with an oligopoly... More
TD Cowen Downgrades Illumina (ILMN) to Hold
February 7, 2025 7:38 AM ESTTD Cowen analyst Dan Brennan downgraded Illumina (NASDAQ: ILMN) from Buy to Hold with a price target of $140.00 (from $177.00).
The analyst comments "We downgrade to Hold post 4Q due to sev. factors: 1) accelerating high throughput (HTP) NGS consumable growth (via... More
